<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612870</url>
  </required_header>
  <id_info>
    <org_study_id>Baden201512</org_study_id>
    <nct_id>NCT02612870</nct_id>
  </id_info>
  <brief_title>Sienna+® Injection Time Study 4 Arms</brief_title>
  <acronym>Sentimag02</acronym>
  <official_title>Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Baden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kantonsspital Baden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with breast cancer normally undergo a labelling with radioactive tracer typically 1
      day before surgery, which enables the surgeon to localize the sentinel lymph node during
      surgery. This pilot study uses the magnetic Sentimag technique to mark the lymph nodes either
      1 or 4-6 days before surgery to investigate the concordance with the standard technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sienna+® is injected either 1 day or 4-6 days before surgery, either retro-mamillary or
      peri-tumorally:

        -  Sienna+® retro-mamillary 1 day before surgery: 10 patients

        -  Sienna+® peri-tumorally 1 day before surgery: 10 patients

        -  Sienna+® retro-mamillary 4-6 days before surgery: 10 patients

        -  Sienna+® peri-tumorally 4-6 days before surgery: 10 patients In each case, Technetium as
           standard technique is employed according to the gold standard protocol one day before
           surgery.

      The Sentimag device is used during surgery to detect the lymph nodes in parallel to the
      standard technique.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate per Patient</measure>
    <time_frame>During surgery</time_frame>
    <description>Proportion of successfully detected sentinel nodes (detection rate per patient) with both methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lymph nodes excised</measure>
    <time_frame>During surgery</time_frame>
    <description>Number of excised sentinel lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodal detection rate</measure>
    <time_frame>During surgery</time_frame>
    <description>Number of detected versus excised sentinel lymph nodes with either method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancy rate</measure>
    <time_frame>1-2 days post surgery</time_frame>
    <description>Number of histologically confirmed malignant sentinel lymph nodes detected with either method.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sienna+ retro and Technetium 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sienna+® is administered retro-mamillary 1 day before surgery for sentinel node marking.
Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sienna+ peri and Technetium 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sienna+® is administered peri-tumorally 1 day before surgery for sentinel node marking.
Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sienna+ retro 4-6 and Technetium 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sienna+® is administered retro-mamillary 4-6 days before surgery for sentinel node marking.
Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sienna+ peri 4-6 and Technetium 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sienna+® is administered peri-tumorally 4-6 days before surgery for sentinel node marking.
Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sienna+ retro</intervention_name>
    <description>Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery</description>
    <arm_group_label>Sienna+ retro and Technetium 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sienna+ peri</intervention_name>
    <description>Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery</description>
    <arm_group_label>Sienna+ peri and Technetium 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sienna+ retro 4-6</intervention_name>
    <description>Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery</description>
    <arm_group_label>Sienna+ retro 4-6 and Technetium 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sienna+ peri 4-6</intervention_name>
    <description>Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery</description>
    <arm_group_label>Sienna+ peri 4-6 and Technetium 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Technetium 1</intervention_name>
    <description>Sentinel node marking with Technetium 1 day before surgery</description>
    <arm_group_label>Sienna+ retro and Technetium 1</arm_group_label>
    <arm_group_label>Sienna+ peri and Technetium 1</arm_group_label>
    <arm_group_label>Sienna+ retro 4-6 and Technetium 1</arm_group_label>
    <arm_group_label>Sienna+ peri 4-6 and Technetium 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a diagnosis of primary breast cancer

          -  Subject has been scheduled for surgery with a sentinel lymph node biopsy procedure

          -  Subject is ≥18 years old at time of consent

          -  Subject has an ECOG performance status of Grade 0-2

          -  Subject has a clinical negative node status

          -  Subject is available for the follow-up

        Exclusion Criteria:

          -  Subject is pregnant or lactating

          -  Subject has a radiological evidence of metastatic cancer

          -  Subject has had previous axilla surgery or reduction mammoplasty

          -  Subject has impaired lymphatic function

          -  Subject has had a preoperative radiation therapy

          -  Subject has iron overload disease or iron/dextran intolerance

          -  Subject has a pacemaker

          -  Subject is under guardianship
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nik Hauser, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Baden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nik Hauser, PD Dr.</last_name>
    <phone>+41 56 486 36 36</phone>
    <email>brustzentrum@ksb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cornelia Leo, PD Dr. med.</last_name>
    <phone>+41 56 486 36 36</phone>
    <email>brustzentrum@ksb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nik Hauser, PD Dr.</last_name>
      <phone>+41 56 486 36 36</phone>
      <email>brustzentrum@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern, Universitätsklinik für Frauen.</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Sager, Dr. med.</last_name>
      <phone>+41 31 632 18 40</phone>
      <email>patrizia.sager@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Thill M, Kurylcio A, Welter R, van Haasteren V, Grosse B, Berclaz G, Polkowski W, Hauser N. The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast. 2014 Apr;23(2):175-9. doi: 10.1016/j.breast.2014.01.004. Epub 2014 Jan 29.</citation>
    <PMID>24484967</PMID>
  </results_reference>
  <results_reference>
    <citation>Douek M, Klaase J, Monypenny I, Kothari A, Zechmeister K, Brown D, Wyld L, Drew P, Garmo H, Agbaje O, Pankhurst Q, Anninga B, Grootendorst M, Ten Haken B, Hall-Craggs MA, Purushotham A, Pinder S; SentiMAG Trialists Group. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann Surg Oncol. 2014 Apr;21(4):1237-45. doi: 10.1245/s10434-013-3379-6. Epub 2013 Dec 10.</citation>
    <PMID>24322530</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghilli M, Carretta E, Di Filippo F, Battaglia C, Fustaino L, Galanou I, Di Filippo S, Rucci P, Fantini MP, Roncella M. The superparamagnetic iron oxide tracer: a valid alternative in sentinel node biopsy for breast cancer treatment. Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12385. Epub 2015 Sep 14.</citation>
    <PMID>26365441</PMID>
  </results_reference>
  <results_reference>
    <citation>Rubio IT, Diaz-Botero S, Esgueva A, Rodriguez R, Cortadellas T, Cordoba O, Espinosa-Bravo M. The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. Eur J Surg Oncol. 2015 Jan;41(1):46-51. doi: 10.1016/j.ejso.2014.11.006. Epub 2014 Nov 15.</citation>
    <PMID>25466980</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Baden</investigator_affiliation>
    <investigator_full_name>Nik Hauser</investigator_full_name>
    <investigator_title>Director Department of Gynecology and Obstetrics</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Sentinel Node</keyword>
  <keyword>Sentinel Node Biopsy</keyword>
  <keyword>Breast Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

